Overview of Hoggar night

Property	Description
Active ingredient	Doxylamine succinate
Form	Oral film-coated tablet
Pharmacological class	Sedating antihistamine (H₁-receptor antagonist)
Common use	Short-term relief of occasional sleep disturbances
Origin	Synthetic (Ethanolamine derivative)

Hoggar night: Classification and Identity of the Active Ingredient

Hoggar night is a branded, non-prescription sleep aid from the manufacturer STADA Arzneimittel AG, whose active substance is the compound Doxylamine succinate. It is formally classified as a first-generation sedating antihistamine, specifically a Histamine H₁-receptor antagonist. This pharmacological identity is clinically recognized for its sedative properties and confirms that the product is a chemically synthesized entity intended to manage difficulties in falling asleep. Clinical information confirms the established role of Doxylamine succinate as a readily available sleep-inducing agent used globally.

Composition, Origin, and Form

The drug's core composition relies on Doxylamine succinate, a synthetic compound derived from the ethanolamine derivative class. Hoggar night is distinguished by its precise monosemiotic preparation, containing only this single active therapeutic substance dedicated to the sedative effect, differentiating it from multi-component cold or pain remedies that may include Doxylamine. The medication is presented in the specific dosage form of an oral film-coated tablet, which is designed for convenient oral administration and differs from liquid or capsule formats.

General Purpose of This Sleep Aid

The primary therapeutic purpose of Hoggar night is the short-term treatment of occasional sleep disturbances in adults. A typical neutral use scenario involves taking the medication when experiencing temporary sleeplessness, such as difficulty falling asleep due to a disruption in routine. By leveraging its function as a central nervous system depressant, the medicine is designed to promote a state of generalized sedation, which in turn supports the desired outcome of shortening the time required to fall asleep. This general indication strictly applies to transient insomnia and not to chronic or continuous sleep disorders.

Regulatory References

Doxylamine - StatPearls - NCBI Bookshelf

What side effects are possible with Hoggar night?

The safety profile of Hoggar night, whose active substance is Doxylamine succinate, is structured around adverse reactions linked to its classification as a sedating antihistamine with anticholinergic properties. All reported effects are categorized according to regulatory frequency standards.

Adverse Reaction Scope

The most frequently reported effects (classified as Common—may affect up to 1 in 10 people) are typically related to Central Nervous System Disorders and the drug's anticholinergic action. These include somnolence (drowsiness), dry mouth, blurred vision, constipation, and difficulty with urination (dysuria). Less frequent, or Uncommon, reactions may involve dizziness, headache, nausea, and vertigo.

Classification	System-Organ Classes Involved
Common	Nervous System, Gastrointestinal, Eye, Renal and Urinary Disorders
Rare	Blood and Lymphatic System Disorders

Serious adverse reactions documented in regulatory sources include the potential for acute angle-closure glaucoma and severe hypersensitivity reactions. Rare, serious blood dyscrasias like leucopenia have been associated with prolonged or long-term use. Side effects, especially somnolence, are officially noted as being more pronounced at the beginning of treatment.

Safety Restrictions and Population Considerations

Official labeling includes safety restrictions that limit the use of the medicine in certain cases. Caution is advised for patients with conditions sensitive to anticholinergic effects, such as narrow-angle glaucoma, prostatic hypertrophy, or urinary bladder-neck obstruction. Similarly, use may be restricted in individuals with severe hepatic or renal impairment due to altered drug clearance. Older adults may be more susceptible to CNS side effects like confusion and increased risk of falls, as well as anticholinergic effects like severe urinary retention, which is why regulatory documents specify increased caution for this population.

The overall safety profile is defined by these classifications, with the most frequent effects being the expected consequence of the drug's primary action.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of Doxylamine succinate, the active ingredient in Hoggar night, is officially documented as potentially leading to severe reactions defined by anticholinergic toxicity. Initial manifestations may include neurological signs such as mental confusion, hallucinations, and profound drowsiness, alongside peripheral effects like mydriasis (fixed and dilated pupils), tachycardia (fast heart rate), and urinary retention.

Overdose can escalate to severe and life-threatening outcomes, including seizures, coma, respiratory failure, and cardiorespiratory arrest. The regulatory documentation also specifies the potential for rhabdomyolysis, a complication that may lead to subsequent acute renal failure.

Immediate medical attention is mandated for all suspected overdose situations. Emergency services or a poison control center must be contacted immediately, particularly if the individual has collapsed, is experiencing trouble breathing, or cannot be awakened. For overdose management, regulatory guidance focuses on symptomatic and supportive care, including decontamination procedures such as activated charcoal administration and continuous monitoring of cardiac activity. Special consideration is noted for children, who are documented to be at a higher risk for severe cardiovascular events.

Therapeutic Uses of Hoggar night

What Hoggar night Treats: Main Uses and Benefits

The primary therapeutic role of this medication is the targeted, short-term symptomatic management of occasional sleep disturbances in adults. Doxylamine may be used to help manage symptoms related to difficulty falling asleep or staying asleep.

This preparation is generally used to address a pronounced symptom associated with transient insomnia, including symptoms related to the difficulty of initiating sleep, and other symptoms of delayed sleep. It is commonly applied to ease sleep disruption caused by specific, temporary events, such as situational stress, nervousness, or disturbances related to jet lag.

Indications commonly associated with its use include acute sleep onset difficulty, occasional sleeplessness, and symptomatic relief during periods of poor nocturnal recovery. This supportive action helps maintain a sense of stability when symptoms are more noticeable.

“The medication may assist in easing symptoms that interfere with daily functioning, such as tiredness and reduced concentration.”

Summary of Relief: Symptomatic Support for Acute Sleep Onset

The core benefit is its role in providing supportive relief for symptoms that temporarily disrupt functional stability, supports patients during episodes of heightened discomfort, and contributes to improved day-to-day comfort.

Regulatory References

NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

The official regulatory profile for Hoggar night (Doxylamine succinate) strictly defines the populations eligible for use, based on formal criteria established by government health agencies.

Approved and Non-Approved Populations

Use of the medication is restricted to Adults aged 18 years and older for the short-term management of occasional sleep disturbances. The safety and efficacy for children and adolescents under 18 years of age have not been established by regulatory authorities; therefore, this age group is prohibited from use.

Contraindications and Restrictions

Several absolute exclusions are formally documented. The medicine is contraindicated in patients with a known hypersensitivity to Doxylamine, as well as those with specific comorbidities such as narrow-angle glaucoma, pheochromocytoma, prostatic hypertrophy with residual urine formation, or a history of seizures. Concurrent use with Monoamine Oxidase Inhibitors (MAOIs) is also an absolute contraindication.

Conditional use is required for patients with impaired liver or kidney function, and for the elderly, due to potential increased sensitivity. The medication is not recommended for pregnant women and is contraindicated for breastfeeding women, as the active substance passes into breast milk.

What should I know about interactions with other medicines?

Interaction Map: Interactions with other medicines and products — official regulatory information for Hoggar night

Property	Value
Medicinal product categories with documented interactions	Monoamine Oxidase Inhibitors (MAOIs), Central Nervous System (CNS) Depressants, other Anticholinergic Agents, potent Inhibitors of CYP liver enzymes (CYP2D6, CYP1A2, CYP2C9).
Specific interacting medicines (if explicitly listed)	Alcohol (Ethanol).
Mechanistic basis of interactions	Pharmacodynamic potentiation (additive CNS depression, intensified anticholinergic effects); Pharmacokinetic alteration (inhibition of metabolic clearance).
Timing-based interaction rules	Co-administration with food is documented to delay the onset of action and reduce absorption.
Population-specific interaction notes	Caution is recommended in patients with hepatic or renal impairment due to the potential for drug or metabolite accumulation.
Interaction-related restrictions	Combination with MAOIs is strictly prohibited; concurrent use with CNS depressants and alcohol is not recommended.

Interaction classifications (high-level)

Property	Value
Interaction severity classification	Contraindicated (MAOIs); Not Recommended (CNS Depressants/Alcohol); Cautionary Avoidance (CYP Inhibitors).
Regulatory basis	FDA Prescribing Information, European Summary of Product Characteristics (SmPC).
Interaction-context constraints	Use can cause false positive results in urine screening tests for methadone, opiates, and phencyclidine phosphate (PCP).

Resulting interaction structure

Official regulatory documentation defines the product’s interaction structure primarily through the risk of pharmacodynamic reinforcement. Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is strictly contraindicated due to the potential for intensified anticholinergic effects. The profile also advises that concurrent use with Central Nervous System (CNS) Depressants, including alcohol, is not recommended due to severe, additive sedative effects. Pharmacokinetic constraints exist related to the drug's metabolic clearance via CYP enzymes; caution is warranted with potent CYP2D6, CYP1A2, and CYP2C9 inhibitors to prevent potential increases in systemic exposure. Furthermore, the official labeling notes that administration with food is documented to delay the onset of the drug's action and reduce absorption. Use may also interfere with certain urine screening tests.

Mechanism of Action

The active substance in Hoggar night, doxylamine, is a first-generation antihistamine that acts primarily in the central nervous system, readily crossing the blood-brain barrier. Its main molecular target is the histamine H1 receptor, to which it binds as a competitive antagonist or inverse agonist. This interaction blocks the binding of the endogenous neurotransmitter histamine, a key molecule in the arousal and wakefulness cascade.

Inhibition of central H1 receptors modulates histaminergic signaling within the tuberomammillary nucleus and downstream projection areas, leading to a reduction in the neuronal activity that promotes alertness. The downstream cascade results in a suppression of the wake-promoting tone on the cerebral cortex. Doxylamine also exhibits non-selective antagonism at muscarinic acetylcholine receptors, contributing an additional dampening effect on central nervous system activity. The system-level physiological consequence of this dual receptor blockade is the modulation of the sleep-wake cycle towards the sleep state, facilitating central nervous system depression.

Dosage and Administration Information

Instruction Map: How to use Hoggar night — Official Administration Guidelines

This section outlines the standardized usage protocol for Doxylamine succinate 25 mg preparations.

Usage Domain	Official Administration Rule
Route and Form	The approved route of administration is Oral via the film-coated or orodispersible (melting) tablet form.
Standard Dosing	The standard dose for adults (typically 12 years and older or 18 years and older depending on the specific product labeling) is 25 mg once daily.
Maximum Dose	The dose should not exceed 25 mg per day as per some labels, although others may permit up to 50 mg (two tablets) for severe sleep disturbances.

Procedural and Course Constraints

The standard schedule requires the 25 mg dose to be taken once daily approximately 30 minutes to 1 hour before the planned bedtime, without regard to meals. If the orodispersible tablet form is used, it is placed on the tongue, allowed to disintegrate, and swallowed with saliva, making additional liquid unnecessary. For all forms, proper use necessitates planning for a sufficient sleep duration of at least 7 to 8 hours after administration, or the dose should not be taken. Treatment is confined to the short term and must not exceed two consecutive weeks of daily use.

Population-Specific Instructions

A lower dose may be necessary for specific patient groups. These populations include older adults (geriatric patients) and individuals with known impaired liver or kidney function, as they may exhibit increased sensitivity to the effects of the active substance.

Connection to the Overall Use Protocol:

These instructions establish a usage protocol that defines the correct oral route and the standard once-daily, pre-bedtime timing for the 25 mg dose. The protocol is structured to enforce a short-term duration limit for the drug's use and clearly outlines specific requirements for dose reduction in vulnerable populations, thereby standardizing administration based on established requirements.

Recent Clinical Evidence

Research evidence / Overview of studies for Hoggar night

Evidence for Short-Term Occasional Sleep Disturbances

Research exploring the properties of the active ingredient, Doxylamine succinate, has been conducted through short-term randomized controlled trials (RCTs) and subsequent Systematic Reviews that summarize the collective data. This research was studied for individuals experiencing short-term or episodic symptom patterns related to occasional difficulty falling asleep, primarily focusing on adult study populations.

Studies report how symptoms evolved in the observed populations by measuring outcomes related to the difficulty initiating sleep, specifically in the context of temporary sleeplessness. The evidence relates to trials assessing short-term symptom patterns, indicating that the substance was studied in the context of temporary sleeplessness over a brief period. However, the evidence quality varies across studies, and some scientific reviews have noted that findings were mixed or limited in their scope.

How Trials Measured Sleep Outcomes

Research examined changes in sleep patterns primarily by applying studies examining patient-reported experiences. Outcomes were related to subjective measures, such as monitoring the time it takes for a person to fall asleep (sleep onset latency) and the individual's perceived quality of sleep. Studies focused on outcomes capturing phases of heightened symptom activity, but the research base often relies on these self-reported assessments.

The available research provides limited insight into objective measures of sleep. For instance, detailed physiological data from sleep laboratory tests, such as polysomnography (PSG), were observed in some studies but were not consistently reported across the full body of evidence. The certainty of evidence for this indication is broadly classified as moderate in scientific assessments.

Evidence Duration and Follow-up Periods

The research base primarily reflects short-term use, relevant in trials assessing episodic symptom patterns. Follow-up durations were limited, with most studies monitoring responses over defined time intervals that typically did not extend beyond four weeks.

Because the research focuses on acute symptom management, there is limited information for long-term outcomes or chronic use patterns. Studies have also observed patterns where the body may develop a reduced response, or tolerance, to the substance with continued, repeated administration. Long-term effects are not fully established, and evidence is limited regarding the durability of response when the medication is used over extended periods.

Research in Specific Patient Groups

The majority of evidence and findings describe group patterns observed in healthy adult populations. Data for certain groups remain insufficient, meaning there is limited information to characterize outcomes for some individuals.

Research has explored the substance in populations such as older adults, where findings suggest that this population may have an altered response pattern. Due to physiological changes with age, research describes patterns in older adult populations where the substance was observed in some studies to have an altered profile. Furthermore, the substance was not evaluated in the primary research for children under 12 years of age, and the data exploring its effects in pregnant or breastfeeding populations are also limited.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Hoggar night (FAQ)

Q: Is Hoggar night a prescription medication or can I buy it over the counter?

A: According to official product information, Hoggar night is classified as an over-the-counter (OTC) or non-prescription medicine. It is labeled for the temporary relief of occasional sleeplessness.

Q: Can Hoggar night be used for long-term sleep issues?

A: Official labeling, consistent across various regulatory authorities, states that the medicine is intended for short-term use only. Regulatory documents state that use for chronic, continuous sleep disorders is not recommended.

Q: Does Hoggar night affect morning wakefulness?

A: Due to its sedative properties, regulatory documents include warnings about a possible residual drowsy effect the next morning. Official use protocols note the need to plan for at least 7 to 8 hours of sleep after administration to help mitigate this risk.

Q: Is the active substance in Hoggar night related to antihistamines?

A: Yes, the active substance, doxylamine, is formally classified as a first-generation sedating antihistamine. This pharmacological classification is related to its action as a H1-receptor antagonist, which contributes to the sedative effect.

Q: Is Hoggar night officially approved for anxiety or stress-related insomnia?

A: The medicine is officially indicated solely for the short-term management of occasional sleep disturbances. It is not approved for specific conditions such as anxiety or stress-related insomnia.

Q: Can Hoggar night cause dependence if used regularly?

A: Official guidelines recommend against use for longer than two consecutive weeks, noting that studies have observed the body may develop a reduced response, or tolerance, with repeated administration.

Q: Is it normal to have strange dreams after taking Hoggar night?

A: Regulatory documents list CNS effects, such as nightmares and hallucinations, as uncommon or rare side effects. These effects are related to the active substance.

Q: What are the most common side effects reported for Hoggar night?

A: The most frequently reported effects (classified as Common) are related to the drug's action in the nervous system and its anticholinergic properties. These common effects include drowsiness, dry mouth, blurred vision, constipation, and difficulty with urination.

Q: Does Hoggar night affect driving ability or concentration?

A: Yes. Official labeling includes a strong warning that the medicine may impair physical and mental abilities. Because of this risk, official labeling includes a strong warning that patients should avoid driving or operating machinery if they experience impairment.

Q: Does Hoggar night affect blood pressure or heart rate?

A: Regulatory documents list tachycardia (a faster heart rate) as an adverse reaction, particularly in cases of overdose. Official caution is noted for patients with pre-existing heart problems or high blood pressure.

Q: Are there any documented cases of overdose with Hoggar night?

A: Official safety information documents potential overdose symptoms and management. These symptoms include the risk of severe CNS effects, seizures, rhabdomyolysis, and cardiorespiratory issues.

Q: Does Hoggar night lose effectiveness over time?

A: Studies and official product information indicate that the body may develop a reduced response, known as tolerance, with continued, repeated administration. This pattern is why short-term use is recommended.

Q: Is Hoggar night available in different strengths or formulations?

A: The active ingredient is commonly available in 25 mg tablet forms, such as film-coated or orodispersible tablets. Depending on the country and brand, it may also be available in liquid formulations (syrup).

Q: Why do official documents specify a limit on the duration of use for Hoggar night?

A: Official documents specify a short-term limit, typically no longer than two weeks. This is because there is limited information on the safety and effects for long-term use, and there is a risk of developing tolerance to the drug’s effects.

Q: Is the research evidence for Hoggar night considered strong by medical authorities?

A: Scientific assessments that summarize the research generally classify the certainty of evidence as moderate for the drug's use in temporary sleeplessness. The research often includes outcomes based on patient-reported experiences.

Q: Can Hoggar night cause dry mouth or dry eyes?

A: Dry mouth and blurred vision are listed in official documents as common side effects related to the medicine's anticholinergic properties. Dry eyes is not explicitly listed in the most frequent categories.

Q: Are the side effects of Hoggar night different for men versus women?

A: There are no general gender differences documented for the overall safety profile. However, official sources note that the elimination half-life may be prolonged in older adult males due to physiological changes.

Q: Does Hoggar night interact with cold and flu medications?

A: Official warnings state that concurrent use is not recommended with other Central Nervous System (CNS) depressants or anticholinergic agents. Both of these may be components in some cold and flu medications.

Q: Is it possible to have an allergic reaction to Hoggar night?

A: Yes. Regulatory information states that the product is contraindicated (should not be used) in patients with known hypersensitivity to the active substance or to any of the inactive ingredients in the formulation.

Q: Do studies show Hoggar night can improve sleep quality, or just reduce time to sleep?

A: Research has examined outcomes related to both the time it takes for a person to fall asleep, known as sleep onset latency, and the individual's perceived quality of sleep. Studies measure both of these aspects of sleep.

Q: Are there any warnings about taking Hoggar night with other sedative medications?

A: Yes. Concurrent use with Central Nervous System (CNS) Depressants, which includes many sedative medications, is not recommended. This is due to the potential for severe, additive sedative effects.

How should Hoggar night be stored and disposed of?

Storing and Disposing of Hoggar Night

The storage of Hoggar Night (doxylamine succinate) must comply with specific regulatory requirements to maintain product stability and ensure safety.

Storage Requirements

The medicine must be stored at a temperature not above 30 C.
Tablets must be kept in the original packaging to ensure protection from moisture and environmental factors.
Doxylamine products must be stored in a safe location that is out of the reach of children, typically in a high or locked space, and kept tightly closed.
The medication must not be used after the expiry date printed on the carton and blister.

Disposal Instructions

Expired or unused tablets must not be disposed of in waste water (e.g., flushing down the toilet).
For proper disposal and environmental protection, patients are directed to ask a pharmacist for instructions on discarding the unused product.
Alternative disposal methods include drug take-back programs or mixing the medicine with an undesirable substance before placing it in household trash.

Hoggar night